Oppenheimer analyst Steve Lichtman backed an Outperform rating and $24 price target on Tandem Diabetes Care (TNDM) after the company announced yesterday FDA approval of the t:slim X2 insulin pump with Basal-IQ which it plans to launch in August. In a research note to investors, Lichtman said that approval timing is in-line, though compatibility with Dexcom's (DXCM) new G6 sensor in the initial approval is upside to expectations. Lichtman remains "bullish" on shares with his above-consensus sales growth estimate in 2019 of +32% y/y and believes international estimates are too conservative.